Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy

Back

HFA Premium Access

Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy

Session: Myocardial Disease

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor R. Rettl (Vienna, AT)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

0 follower

7 more presentations in this session

Predictive role of myocardial fibrosis and extracellular myocardial volume in sudden cardiac death and ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy

Speaker: Mrs N. Rineiska (Minsk, BY)

Alcohol septal ablation is safe in young patients

Speaker: Doctor A. Batzner (Wurzburg, DE)

Mavacamten improves symptoms of shortness of breath in patients with obstructive hypertrophic cardiomyopathy (HCM): analysis of the HCM Symptom Questionnaire in the phase 3 EXPLORER trial

Speaker: Doctor S. Naidu (New York, US)

Left atrial strain in cardiac amyloidosis

Speaker: Doctor I. Fabiani (Pisa, IT)

DPD scintigraphy fails to detect transthyretin cardiac amyloidosis in Val30Met mutation carriers with early onset disease.

Speaker: Doctor A. Olivella (Barcelona, ES)

Access the full session

Myocardial Disease

Speakers: Doctor R. Rettl, Mrs N. Rineiska, Doctor A. Batzner, Doctor S. Naidu, Doctor I. Fabiani...

Access

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources